Comparison
DSIP vs. Melanotan II
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
62568-57-4
121062-08-6
Molecular weight
848.81 g/mol
1024.18 g/mol
Half-life
0.1 h
1 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Mechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
9
of which in humans
1
5
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
1
6
Legal status
Full entries
Frequently asked questions
- What is the difference between DSIP and Melanotan II?
- DSIP is classified as "Research other", while Melanotan II is classified as "Research other". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Melanotan II?
- The highest available evidence level is "Human trial" for DSIP and "Human trial" for Melanotan II. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Melanotan II in Germany and the United States?
- Germany: DSIP — Unapproved, Melanotan II — Unapproved. United States: DSIP — Unapproved, Melanotan II — Unapproved. These are factual summaries with source and review date on the individual pages.